Replies to post #1268 on Sequiam Biometrics (fka SQUM)

[analystslie]

Numbers were basically what I was expecting. Product sales should be extraordinary in 4th quarter as just began shipping very late September with bulk coming in 4th quarter. Biolock shipments just recently started with more to hopefully hear about in the coming weeks. Biovault shipped later than expected and at this point expecting excellent numbers from Biovault sales in 4th quarter as well.

Cash was obviously low although warrant conversions we discussed a few weeks ago should have eliminated those concerns.

If you look at the 10Q and read the interview today it should give you some perspective on last quarter and the direction SQUM is now going.

The financials in 4th quarter should tell a story.

[mick]

lan, you will find out ihub is the best to receive messages, dd and ta.

it is nice to see you are a shareholder. squm

maybe some shareholders at R/B will see us and like our messages here.

[analystslie]

Concerning recent Financials:
Below excerpt taken from CEO Interview this morning.

EDS: In looking at the recent Financials, combined with all the recent positive good Company sales related news, do you anticipate that operations would turn profitable, in the near term?

Nick VandenBrekel:

As I stated earlier, Sequiam is now transitioning from research and development into sales. We are actually a little ahead of our sales projections and based on current orders and product deliveries we anticipate profitability in the first quarter of 2007. We had originally anticipated profitability late in 2007 but our products are being so well received that we have drastically moved up our time table. It is clearly an excited time for us.

EDS: I know Investors are always interested in a Company’s Financing arrangements. Do you currently have a new financing arrangement in place? Does this current financing achieve the Company needs without significant shareholder dilution?

Nick VandenBrekel:

We are always aware of the fact that in order to grow fast we need to be able to fund this growth. Presently we are working on doing exactly that but without having to dilute the shareholder base. It will achieve the Company’s needs and even clean up the balance sheet considerably. The credibility of our recent successes has brought about financial facilities previously not available to companies our size.

EDS: Just to confirm, are the shares outstanding around 80 million shares and the float is around 30 million shares?

Nick VandenBrekel:

That is roughly the number